Achillion Pharmaceuticals Inc., of New Haven, Conn., named Jerome Birnbaum senior vice president of research.
Albany Molecular Research Inc., of Albany, N.Y., named Barry Berkowitz corporate vice president of its Bothell Research Center in Washington and promoted Dwight Baker to head of operations of the center. The company also promoted James Grates to vice president, operations, Michael Ironside to director of chemical development, Andrea Schulz to director of human resources, Dan Lowenski to director of environmental health and safety, David Coon to director of facilities, Brian Gregg to assistant director of combinatorial chemistry and William Earley to section head, combinatorial chemistry. The company also made 50 other promotions.
Alexion Pharmaceuticals Inc., of Cheshire, Conn., appointed Thomas Dubin vice president and general counsel.
Atrix Laboratories Inc., of Fort Collins, Colo., appointed Brian Richmond chief financial officer.
Aurora Biosciences Corp., of San Diego, appointed Williams Ettouati vice president, business development; Christopher Krueger general counsel and vice president, strategic alliances; Pamela Fritz vice president, human resources; and Brian Pollok vice president, discovery biology.
Axiom Biotechnologies Inc., of San Diego, added Paul England, Paul Insel, Curtis Klaassen and David Webb to its scientific advisory board.
Axiom Biotechnologies Inc., of San Diego, appointed Michael Kozlowski chief operating officer, Damien Dunnington vice president of discovery research and Steven Brown director of molecular pharmacology. It also added Eric Feldman, Russell Glass and Walter Moos to its board.
Baxter International Inc., of Deerfield, Ill., appointed Norbert Riedel chief scientific officer.
Cel-Sci Corp., of Vienna, Va., appointed Richard Kinsolving to its board of directors.
Celsion Corp., of Columbia, Md., appointed Daniel Reale president of its BPH Division and executive vice president of the parent corporation.
Ceregene Inc., of San Diego, named Jeffrey Ostrove president and chief operating officer.
Cholestech Corp., of Hayward, Calif., appointed William Burke vice president of finance and chief financial officer.
Crucell NV, of Leiden, the Netherlands, appointed Arthur Lahr executive director of business development for its antibody business.
Cubist Pharmaceuticals Inc., of Cambridge, Mass., appointed Dinendra Sen president and chief operating officer.
Cypress Bioscience Inc., of San Diego, appointed Charles Nemeroff to its board.